How to administer albumin infusion in a patient with hypoalbuminemia, edema, and sepsis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Albumin Administration in Hypoalbuminemic, Edematous Patients with Sepsis

Direct Recommendation

In a patient with hypoalbuminemia (albumin 20.21 g/L), edema, and sepsis, administer 20% albumin at 20 grams every 8 hours for 3 days as an adjuvant to crystalloid resuscitation, targeting a serum albumin level ≥30 g/L, while closely monitoring for circulatory overload. 1


Clinical Context and Rationale

When to Use Albumin in Sepsis

  • Albumin should be considered as second-line therapy only after adequate crystalloid resuscitation (minimum 30 mL/kg) when shock persists or worsens despite initial fluid therapy. 1, 2

  • The Surviving Sepsis Campaign recommends albumin in addition to crystalloids specifically when patients require large volumes of crystalloids without adequate hemodynamic improvement. 3, 1

  • In refractory septic shock with hypoalbuminemia, 20% albumin shows greater benefits than 4-5% albumin, including improved cardiovascular function, shorter vasopressor duration (3 vs 4 days), and lower volume requirements. 1, 2

Specific Dosing Protocol for Your Patient

For septic shock with hypoalbuminemia:

  • Administer 20% albumin solution at 20 grams every 8 hours for 3 days as the evidence-based protocol. 1
  • Target serum albumin concentration of ≥30 g/L (3.0 g/dL). 3, 1
  • The hyperoncotic 20% solution will expand plasma volume by 3-4 times the infused volume by withdrawing fluid from interstitial spaces. 4

Administration technique:

  • May be given undiluted or diluted in 0.9% sodium chloride or 5% dextrose in water. 4
  • If sodium restriction is required, dilute only in sodium-free solutions like 5% dextrose. 4
  • Use only 16-gauge needles or dispensing pins for vial access. 4

Critical Monitoring Requirements

Preventing Circulatory Overload in Edematous Patients

This is the most important safety consideration in your edematous patient:

  • Infusion rate should not exceed 2 mL per minute in hypoalbuminemic patients with normal or expanded blood volumes to prevent circulatory embarrassment and pulmonary edema. 4

  • Monitor closely for signs of circulatory overload, especially given the patient's pre-existing edema and the hyperoncotic nature of 20% albumin. 1, 4

  • Use transthoracic echocardiography to evaluate volume status and cardiac function during resuscitation. 1

Hemodynamic Targets

  • Maintain mean arterial pressure (MAP) ≥65 mmHg as the initial vasopressor goal. 1
  • Monitor for normalization of lactate and urine output ≥0.5 mL/kg/h as indicators of shock reversal. 1
  • Assess cardiovascular SOFA scores, which should improve with 20% albumin therapy. 2

Managing the Edema Component

Albumin Plus Diuretics Strategy

For the edematous component in your hypoalbuminemic septic patient:

  • Consider combining 25% albumin (100 mL) with furosemide twice daily to facilitate diuresis while maintaining oncotic pressure. 5, 6

  • Administer diuretics within 2 hours following albumin infusion for optimal effect. 6

  • While urine output may be higher at 6 hours with albumin-furosemide combination, evidence shows no difference at 24 hours compared to furosemide alone in critically ill patients. 3

Important caveat: The primary goal in acute sepsis is hemodynamic stabilization, not immediate diuresis. Aggressive diuresis should be deferred until shock is reversed and the patient is hemodynamically stable. 1


Evidence Quality and Limitations

What the Evidence Shows

  • The largest trial (ALBIOS) with 1,818 septic patients found no mortality benefit at 28 days with 20% albumin (RR 1.00; 95% CI 0.87-1.14), but did show improved cardiovascular function and reduced vasopressor requirements. 3, 2

  • Meta-analysis of 17 randomized trials showed reduced mortality with albumin versus crystalloids in severe sepsis/septic shock (OR 0.78; 95% CI 0.62-0.99). 1

  • Albumin does not reduce the need for kidney replacement therapy or improve mortality in most critically ill populations. 3

Why Use It Despite Mixed Evidence?

  • The recommendation is based on improved hemodynamic parameters, reduced vasopressor duration, and better fluid balance rather than mortality benefit alone. 1, 2

  • In hypoalbuminemic patients specifically, albumin's volume effectiveness appears greater when serum albumin levels are low, making it more rational in your patient with albumin 20.21 g/L. 7

  • Albumin has pleiotropic effects including antioxidant properties, positive effects on vessel wall integrity, and potential renal protective effects that may be clinically relevant in sepsis. 8


Common Pitfalls to Avoid

Do not use albumin as first-line fluid resuscitation: Crystalloids remain the first-line treatment, with albumin reserved for refractory shock or when large crystalloid volumes (>30 mL/kg) have been administered without adequate response. 3, 1, 2

Do not use albumin for nutritional purposes or to simply correct hypoalbuminemia: The hypoalbuminemia in sepsis reflects capillary leak and inflammation, not nutritional deficiency. 5, 9

Avoid rapid infusion in edematous patients: The 2 mL/minute maximum rate is critical to prevent pulmonary edema in patients with pre-existing fluid overload. 4

Do not continue albumin indefinitely: The evidence supports a 3-day course; prolonged administration should not be considered a source of nutrition and requires initiation of appropriate nutritional support. 1, 4

Monitor for cardiac contraindications: Excessive albumin can cause pulmonary edema and respiratory failure, particularly in patients with underlying cardiac dysfunction. 1


Cost Consideration

  • Albumin 20% costs approximately $130 per 25g dose, making it significantly more expensive than crystalloid alternatives. 10
  • This cost must be weighed against potential benefits of reduced vasopressor duration and improved hemodynamic stability in refractory shock. 1, 2

References

Guideline

Refractory Shock Management with Albumin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Albumin Therapy in Critically Ill Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Albumin: a comprehensive review and practical guideline for clinical use.

European journal of clinical pharmacology, 2024

Research

Hypoalbuminemia.

Internal and emergency medicine, 2012

Guideline

Human Albumin 20% in Neonates: Evidence-Based Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.